Key result
Dyslipidemia was associated with significantly lower circulating ANGPTL8/betatrophin compared to controls in males (17.0 vs 27.8 ng/mL) and females (27.0 vs 50.0 ng/mL; P<.001).
Why the study?
Are circulating concentrations of ANGPTL8/betatrophin altered in individuals with dyslipidemia compared to controls?
Population
177 subjects from two selected case-control dyslipidemic cohorts, including individuals with high or low…
Design
Case-control
Authors
Loading...
ANGPTL8 levels add no immediate clinical utility in dyslipidemia; leaves open mechanistic and therapeutic roles.
Case-Control (n=177)
Are circulating concentrations of ANGPTL8/betatrophin altered in individuals with dyslipidemia compared to controls?
p-value: p=<.001
Serum ANGPTL8/betatrophin concentrations are significantly lower in individuals with dyslipidemia, suggesting a role for this protein in lipid metabolism and its potential as a therapeutic target.
Gómez‐Ambrosi et al. (2016) conducted a case-control in Dyslipidemia (n=177). Dyslipidemia vs. Controls was evaluated on Circulating concentrations of ANGPTL8/betatrophin (p=<.001). Dyslipidemia was associated with significantly lower circulating ANGPTL8/betatrophin compared to controls in males (17.0 vs 27.8 ng/mL) and females (27.0 vs 50.0 ng/mL; P<.001).